With the low concentration, average recovery was 101.02% (SD = 3.98) for the males and 105.34% (SD = 5.35) for the females (see Supplementary Table S1)
What is less commonly discussed is the composition of that weight loss
Tirzepatide Dual GIP/GLP-1 agonist for enhanced effects
For this reason, GHRP-6 is often discussed when researchers are exploring growth hormone release alongside appetite support mechanisms
Weight-Loss Pace Compounded GLP-1 + GIP Women often report: Steady, consistent loss Early progress within weeks Easier plateau-breaking Ozempic Women often report: Slow and steady loss Noticeable appetite reduction Effective long-term progress with consistency Both are supportive the best one depends on whether you want dual-pathway help or single-pathway appetite control
Xu F, Cao H, Chen Z, Gu H, Guo W, Lin B, Weng J